US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
pharma · Chronic Kidney Disease Requiring Chronic Dialysis · UNCY
Unicycive Therapeutics
Unicycive Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Los Altos, USA HQ
2016 Founded
23 Employees
Public company Type
UNCY · NYSE Ticker
Company details
- Status
- Public
- HQ
- Los Altos, USA
- Founded
- 2016
- Employees
- 23
- Programs
- 1
- Drugs
- 3
- Patents
- 4
Unicycive Therapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Unicycive Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Unicycive Therapeutics in public FDA and regional records. Molecular target: Phosphate.
- Target
- Phosphate
- Mechanism
- Phosphate sequestering agent
-
US regulatory status: approved. Molecular target: Phosphate.
- Target
- Phosphate
- Mechanism
- Phosphate sequestering agent